Antithrombotic Therapies and Body Mass Index: Does One Size Fit All?

JACC Cardiovasc Interv. 2022 Oct 10;15(19):1961-1964. doi: 10.1016/j.jcin.2022.08.031.

Authors

Joaquin E Cigarroa¹, H V Skip Anderson²

Affiliations

¹ Division of Cardiology, Knight Cardiovascular Institute, Oregon Health and Sciences University, Portland, Oregon, USA. Electronic address: cigarroa@ohsu.edu.
² University of Texas Health Science Center Houston, McGovern Medical School, Memorial Hermann Heart & Vascular Institute, Houston, Texas, USA.

PMID: 36202564
DOI: 10.1016/j.jcin.2022.08.031

No abstract available

Keywords: PCI; antiplatelet agents; bleeding.

Publication types

Editorial
Comment

MeSH terms

Anticoagulants
Atrial Fibrillation* / drug therapy
Body Mass Index
Fibrinolytic Agents / adverse effects
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors
Treatment Outcome

Substances

Anticoagulants
Fibrinolytic Agents
Platelet Aggregation Inhibitors